Interim results of targeted therapy of patients with metastatic kidney cancer in Moscow (for the period from June 2005 to July 2015)
https://doi.org/10.17650/1726-9776-2016-12-2-14-17
Abstract
The paper provides the first interim analysis of a database including information on 806 metastatic kidney cancer patients receiving targeted therapy in the cancer facilities of the Moscow Healthcare Department. It shows a comparative analysis of the periods of first-line targeted therapy with different drugs until progression is established.
About the Authors
V. I. Shirokorad
Moscow City Cancer Hospital № 62, Moscow Healthcare Department; 27 Istra Settlement, Moscow Region, 143423, Russia
Russian Federation
Russian Federation
A. N. Makhson
Moscow City Cancer Hospital № 62, Moscow Healthcare Department; 27 Istra Settlement, Moscow Region, 143423, Russia
Russian Federation
Russian Federation
I. G. Rusakov
City Clinical Hospital № 57, Moscow Healthcare Department; 32 11st Parkovaya St., Moscow, 105077, Russia
Russian Federation
Russian Federation
G. P. Kolesnikov
Moscow City Cancer Hospital № 62, Moscow Healthcare Department; 27 Istra Settlement, Moscow Region, 143423, Russia
Russian Federation
Russian Federation
S. V. Kostritskiy
Moscow City Cancer Hospital № 62, Moscow Healthcare Department; 27 Istra Settlement, Moscow Region, 143423, Russia
Russian Federation
Russian Federation
K. Yu. Kashintsev
Moscow City Cancer Hospital № 62, Moscow Healthcare Department; 27 Istra Settlement, Moscow Region, 143423, Russia
Russian Federation
Russian Federation
V. I. Borisov
Oncology Clinical Dispensary № 1, Moscow Healthcare Department; 17/1 Baumanskaya St., Moscow, 105005, Russia
Russian Federation
Russian Federation
M. I. Popov
Moscow City Cancer Hospital № 62, Moscow Healthcare Department; 27 Istra Settlement, Moscow Region, 143423, Russia
Russian Federation
Russian Federation
M. Yu. Shchupak
Moscow City Cancer Hospital № 62, Moscow Healthcare Department; 27 Istra Settlement, Moscow Region, 143423, Russia
Russian Federation
Russian Federation
N. V. Kirdakova
Oncology Clinical Dispensary № 1, Moscow Healthcare Department; 17/1 Baumanskaya St., Moscow, 105005, Russia
Russian Federation
Russian Federation
S. V. Mishugin
City Clinical Hospital № 57, Moscow Healthcare Department; 32 11st Parkovaya St., Moscow, 105077, Russia
Russian Federation
Russian Federation
M. R. Maturov
District Oncology Dispensaries, Moscow Healthcare Department (Western Administrative District, South-Western Administrative District, Southern Administrative District, South-Eastern Administrative District, Eastern Administrative District, North-Eastern Administrative District, Central Administrative District, Zelenograd Administrative District)
Russian Federation
Russian Federation
A. G. Vinogradskiy
District Oncology Dispensaries, Moscow Healthcare Department (Western Administrative District, South-Western Administrative District, Southern Administrative District, South-Eastern Administrative District, Eastern Administrative District, North-Eastern Administrative District, Central Administrative District, Zelenograd Administrative District)
Russian Federation
Russian Federation
S. D. Shikhov
District Oncology Dispensaries, Moscow Healthcare Department (Western Administrative District, South-Western Administrative District, Southern Administrative District, South-Eastern Administrative District, Eastern Administrative District, North-Eastern Administrative District, Central Administrative District, Zelenograd Administrative District)
Russian Federation
Russian Federation
E. V. Gaydamaka
District Oncology Dispensaries, Moscow Healthcare Department (Western Administrative District, South-Western Administrative District, Southern Administrative District, South-Eastern Administrative District, Eastern Administrative District, North-Eastern Administrative District, Central Administrative District, Zelenograd Administrative District)
Russian Federation
Russian Federation
N. A. Apol’skaya
District Oncology Dispensaries, Moscow Healthcare Department (Western Administrative District, South-Western Administrative District, Southern Administrative District, South-Eastern Administrative District, Eastern Administrative District, North-Eastern Administrative District, Central Administrative District, Zelenograd Administrative District)
Russian Federation
Russian Federation
M. U. Shushakov
District Oncology Dispensaries, Moscow Healthcare Department (Western Administrative District, South-Western Administrative District, Southern Administrative District, South-Eastern Administrative District, Eastern Administrative District, North-Eastern Administrative District, Central Administrative District, Zelenograd Administrative District)
Russian Federation
Russian Federation
E. R. Babaev
District Oncology Dispensaries, Moscow Healthcare Department (Western Administrative District, South-Western Administrative District, Southern Administrative District, South-Eastern Administrative District, Eastern Administrative District, North-Eastern Administrative District, Central Administrative District, Zelenograd Administrative District)
Russian Federation
Russian Federation
A. A. Vorontsova
District Oncology Dispensaries, Moscow Healthcare Department (Western Administrative District, South-Western Administrative District, Southern Administrative District, South-Eastern Administrative District, Eastern Administrative District, North-Eastern Administrative District, Central Administrative District, Zelenograd Administrative District)
Russian Federation
Russian Federation
A. M. Ivanov
District Oncology Dispensaries, Moscow Healthcare Department (Western Administrative District, South-Western Administrative District, Southern Administrative District, South-Eastern Administrative District, Eastern Administrative District, North-Eastern Administrative District, Central Administrative District, Zelenograd Administrative District)
Russian Federation
Russian Federation
F. R. Amosov
District Oncology Dispensaries, Moscow Healthcare Department (Western Administrative District, South-Western Administrative District, Southern Administrative District, South-Eastern Administrative District, Eastern Administrative District, North-Eastern Administrative District, Central Administrative District, Zelenograd Administrative District)
Russian Federation
Russian Federation
References
1. Давыдов М.И., Аксель Е.М. Заболеваемость злокачественными новообразованиями и смертность от них населения стран СНГ в 2008 г. Вестник РОНЦ им. Н.Н. Блохина 2010;(2):48–9. [Davydov М.I., Аksel’ Е.М. Morbidity and fatality, caused by malignant neoplasms to the population of CIS countries in 2008. Herald of N.N. Blokhin RCRC 2010;(2): 48–9. (In Russ.)].
2. Алексеев Б.Я., Анжиганова Ю.В., Лыков А.В. и др. Особенности диагностики и лечения рака почки в России: предварительные результаты многоцентрового ко оперированного исследования. Онкоурология 2012;(3):24–31. [Аlekseev B.Ya., Аnzhiganovа Yu.V., Lykov А.V. et al. Peculiarities of the diagnostics and treatment of the kidney cancer in Russia: preliminary results of the multicenter cooperated studies. Оnkourologiya = Cancer Urology 2012;(3):24–31. (In Russ.)].
3. Каприн А.Д., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2014 году. М., 2015. 236 с. [Kaprin А.D., Starinskiy V.V., Petrova G.V. Status of oncologic assistance to the population of Russia in 2014. Мoscow, 2015. 236 p. (In Russ.)].
4. Матвеев В.Б., Волкова М.И. Последовательная таргетная терапия при диссеминированном раке почки. Онкоурология 2013;(1):28–33. [Маtveev V.B., Volkova М.I. Consecutive target therapy at the disseminated kidney cancer. Оnkourologiya = Cancer Urology 2013;(1):28–33. (In Russ.)].
5. Широкорад В.И., Махсон А.Н. Первые результаты таргетной терапии при раке почки в Москве. Онкоурология 2013;(3):24–9. [Shirokorad V.I., Мakhson A.N. First results of target therapy at the kidney cancer in Moscow. Оnkourologiya = Cancer Urology 2013;(3):24–9. (In Russ.)].
6. Motzer R.J., Hutson T., Tomczak P. et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27(22):3584–90.
7. Hass N.B., Manola J., Uzzo R.G. et al. Initial results from ASSURE (E2805): Adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase III trial. J Clin Oncol 2015; 33 Suppl 7:abstr 403.
8. Алексеев Б.Я., Калпинский А.С. Применение таргетных препаратов в лечении метастатического рака почки: последовательное назначение или комбинация. Онкоурология 2010;(4):16–22. [Аlekseev B.Ya., Kalpinskiy А.S. Application of target substances in the treatment of the metastatic kidney cancer: consecutive administration or combination. Оnkourologiya = Cancer Urology 2010;(4):16–22. (In Russ.)].
Review
For citations:
Shirokorad V.I., Makhson A.N., Rusakov I.G., Kolesnikov G.P., Kostritskiy S.V., Kashintsev K.Yu., Borisov V.I., Popov M.I., Shchupak M.Yu., Kirdakova N.V., Mishugin S.V., Maturov M.R., Vinogradskiy A.G., Shikhov S.D., Gaydamaka E.V., Apol’skaya N.A., Shushakov M.U., Babaev E.R., Vorontsova A.A., Ivanov A.M., Amosov F.R. Interim results of targeted therapy of patients with metastatic kidney cancer in Moscow (for the period from June 2005 to July 2015). Cancer Urology. 2016;12(2):14-17. https://doi.org/10.17650/1726-9776-2016-12-2-14-17
Views:
1394
Email this article 